For the past twenty-seven years we have offered a Mentor Program to our students. The purpose of this Program is to provide you and a small group of your colleagues with the opportunity to personally discuss any topic of mutual interest with a leading locally-based, nationally recognized health care executive. Below is a list of mentors and their organization affiliation. To diversify their experience, students choose a different mentor for their second year. We will arrange lunches that will consist of the mentor and five students, as well as one on one sessions with the mentor. The program runs from January 2014 thru March 2014. If you are interested in lunch or a one on one meeting with a mentor listed below go to this site
and sign up . We are sure that you will find it to be one of the most rewarding educational experiences you will have at Kellogg in 2014.
is the senior vice president and chief financial officer of Exact Sciences. Prior to joining Exact, Maneesh served as chief financial officer of Third Wave Technologies, a molecular diagnostic company focused on cervical cancer screening, from January 2006 until the company’s acquisition by Hologic in July 2008. He joined Third Wave in January 2003 as director of strategy and was promoted successively to vice president and senior vice president in 2004. Prior to joining Third Wave, Arora was director of corporate strategy for Nalco Chemical Company. He began his career at Kraft Foods as a financial analyst and held several positions of increasing responsibility during his nine years there. Arora earned a bachelor's degree in economics from the University of Chicago and a master of business administration degree from the Kellogg Graduate School of Management.
has been CEO and Director of Orteq Limited, a privately held start-up, since March 2006. Orteq has a unique polymer technology platform for sports surgery soft tissue repair. Its first product, Actifit, for the treatment of irreparable meniscus tears or defects in the knee, is on the market in Europe and other rest of world markets. The company expects FDA approval to start a US clinical trial this summer.
Prior to joining Orteq, Mrs. Blanco spent almost fourteen years at Baxter Healthcare, a worldwide leader in pharmaceuticals and medical devices, in various divisional president roles ending as President of Europe, and prior to that, she spent eight years as Executive Vice President at Microdot Inc.,
Mrs. Blanco was born in the US, but has lived in Europe since May of 2000. She has an undergraduate degree magna cum laude and Masters degree from the University of Illinois. She holds an MBA magna cum laude from the Northwestern University Kellogg Graduate School of Management.
Mrs. Blanco resides in London. She is married with a grown daughter. She is an avid recreational runner, reader and novice art collector.
(Kellogg '81) is the Founder and Chairman of the Pharmaceutical Biomedical Research Consortium [PBRC]. The PBRC is a 501 C3, which serves to advance the field of medicine through the development and implementation of high quality “pre-competitive” biomedical research consortia, across the pharmaceutical industry and academia. The Consortium currently has a major program international effort underway focused on the pharmacogenetics of serious adverse drug reactions [i.e. International Serious Adverse Event Consortium]. Resulting data and outputs from these efforts are being made available to all qualified researchers, free of IP constraints. Until October 2007, Mr. Holden concurrently held the position of Senior Vice President of Corporate and Market Development at Illumina, a leading provider of analytical systems and service for the analysis of genetic variation. It was named the NASDAQ’s fastest growing technology company in 2006 and 2008. In 2000, he was the principal founder of First Genetic Trust, a venture capital [Venrock] backed development stage biotechnology/informatics firm. He served as the company’s Chairman and CEO from 2000-2006. First Genetic Trust develops secure web-based applications to support the acquisition, storage, management, and analysis of genetic and medical data in drug discovery, development and clinical practice. The company was sold in the spring of 2006 to Cerner, Inc. Mr. Holden also served as Chairman of the SNP Consortium. Before serving as Chairman of the SNP Consortium, Mr. Holden was CEO of The SNP Consortium Ltd. which was a nonprofit entity dedicated to creating a high quality, high-density single nucleotide polymorphism (SNP) map of the human genome. Prior to his leadership role with the SNP Consortium Ltd., he was CEO and a Director of Celsis International PLC, an international biotechnology company. He spent the majority of his career as an executive with Baxter International. Mr. Holden serves on a number of non-profit boards. He is Chairman of the Advisory Board for the Biotechnology Management Program at the J.L. Kellogg Graduate School of Management. He is a director of iBIO, the Chicago Children’s Hospital Research Institute, and the Illinois Technology Development Alliance. Mr. Holden has won numerous leadership awards, including being a recipient of the Laura Jackson Achievement Award for outstanding leadership in the healthcare industry from Northwestern University.
is President and Chief Executive of Healthios, Inc. (“Healthios”), a healthcare merchant banking firm. Throughout his professional career, Mr. Loucks has been active as an advisor, investor, and general manager across the global healthcare industry, in the process nurturing a unique perspective on the sources of success and the nature of value creation. Healthios was founded in 2005 by Mr. Loucks, following several years spent as Managing Partner of the Aethena Group, LLC, which is a private equity partnership with a broad portfolio of investment interests. During his tenure with Aethena, Mr. Loucks positioned that firm to become one of the most active investors in the global healthcare industry, having participated in more than (40) transactions from 2001 through 2004, representing aggregate enterprise values in excess of $5 billion. Prior to founding the Aethena, from 1998 until 2000, Mr. Loucks served as President and CEO of Physician Dynamics, Inc. (“PDI”), a fully-integrated provider of patient education and disease management solutions for patients afflicted with chronic and acute diseases. Services comprising patient & family education, compliance management, utilization review, outcomes measurement, informed consent, and remote monitoring were sold to hospitals, health plans, and providers throughout the U.S. Among his duties at Robertson Stephens, Mr. Loucks was a founder of the Special Situations practice and he directed that firm’s first international financing initiatives for companies based in Europe, Israel, India, and China. Schooled in Europe, and later a graduate of the Lawrenceville School, of Yale University, and of the Kellogg Graduate School of Management at Northwestern University, Mr. Loucks is multi-lingual and has spent more than 15 years living and working internationally.
is a Principal with ZS Associates in Evanston, Illinois, and is currently the leader of ZS’ Medical Products and Services Practice. His experience at ZS includes helping clients improve the effectiveness of their marketing and sales efforts in a broad range of areas. Pete’s practice area expertise spans a broad scope from market strategy; such as opportunity assessment, product strategy, organization design, and go-to-market strategy; to organizational effectiveness drivers, such as incentive compensation, targeting and account planning. His clients at ZS have been primarily in the medical devices and medical diagnostics industries. Pete has authored several articles and white papers on topics such as medical device industry trends and their implications, go-to-market strategy, sales effectiveness and incentive compensation. Pete is also currently a member of the sales and distribution advisory board for MX magazine. Pete joined ZS Associates in 1996. Prior to joining ZS Pete worked for The Dow Chemical Company in various research and development and commercial roles. Pete has a Master of Management with distinction from the Kellogg School of Management at Northwestern University. Pete also holds a BSE in Chemical Engineering from Princeton University.
has over thirty-five years of healthcare experience with the last thirty in investment banking. From the Chicago office of Bank America Merrill Lynch he is responsible for providing investment banking services to a variety of health care clients throughout the country. Mr. Mieling’s client experience includes freestanding hospitals, multi state integrated health systems, managed care, physician groups and long term care. A few of his clients include Hospital Health System (IL, WI), Munson Healthcare (MI), Franciscan Alliance, Inc. (IN, IL) and Baptist Memorial Health Care (AR, MS, TN). Prior to joining Merrill Lynch & Co. in 1997, he was the National Director – Health Care for the investment banking firm of John Nuveen & Co. In his capacity of National Director, Mr. Mieling was responsible for all underwriting, merger and acquisition activities of the firm. Before joining John Nuveen & Co. in 1981, Mr. Mieling was a Senior Manager with Ernst & Young in Chicago from 1975 to 1981, where he provided consulting services to the health care industry. Prior to Ernst & Young he was the Chief Financial Officer for a hospital in the Hospital Sisters Health System, Springfield, Illinois.
Mr. Mieling received his B.S. in Biochemistry from the University of Illinois at Urbana and his M.B.A. from the same institution. In addition, he is a Certified Public Accountant.
is President of NorthShore Skokie Hospital part of NorthShore University HealthSystem, a comprehensive, fully integrated, healthcare delivery system that serves the Chicago region with four hospitals and over 2,400 physicians. In her time at NorthShore Murtos has worked extensively in medical group development, physician alignment, clinical service line management, mergers and acquisitions as well as strategy and business development.
In her current role as President of Skokie Hospital, Murtos provides leadership promoting organizational performance and driving quality, loyalty and growth. In addition to her leadership role at Skokie Hospital, Murtos oversees Corporate Marketing, Communications and Business Development for NorthShore.Prior to joining NorthShore, Murtos worked with Deloitte Consulting where she assisted healthcare providers, payors and manufacturing clients with operational improvement, market strategy, delivery system integration and care management. Murtos holds a bachelor’s degree from the University of Illinois at Urbana-Champaign and master degrees in Business Administration and Public Policy from the University of Chicago. She has served in leadership roles with the University of Chicago Graduate Program in Health Administration & Policy Executive Council, The North Shore Board of the American Cancer Society and The Evanston Chamber of Commerce. She currently serves on the board of the North Suburban Healthcare Foundation and on the Advisory Board for the Kindness Connection which promotes volunteerism to school age children.
is director of Pharma marketing at Baxter. He is a seasoned executive in the pharmaceutical industry with global expertise and responsibilities in both strategic and operational marketing. He’s developed a strong acumen of the industry challenges and opportunities throughout his engagement in Drug Delivery. He’s recognized for his focus on growth and investment through customer-centered business strategy and ruthless execution. Olivier has acquired a diverse cultural understanding through all the countries he worked in: UK, Belgium, Germany, Italy, Spain, France, US and Canada. Additionally, his global responsibilities led him to build business relationships with Japan, China, Australia, New Zealand, Latin America and Eastern Europe. He is a Kellogg alum (EMP61, 2005). Being a Board Member and Chairman for fund-raising at the French American Chamber of Commerce based in Chicago drives him to play a significant role in the economic relationships between the US and France, his native country.